The in¯uence of obesity on blood pressure and plasma lipoproteins, glucose and insulin levels was investigated in patients with familial combined hyperlipidaemia (FCH). Sixty seven FCH patients mean age 49.0 AE 8.9 y (45 male, 22 female) de®ned as obese (BMI ! 27 kg/m 2 , n 39) or non-obese (BMI`27 kg/m 2 , n 28) were compared with control subjects matched for age, gender and body weight. Blood pressure, plasma lipoproteins, glucose and insulin were measured at baseline and following standard oral glucose load. The analysis indicate that FCH subjects with BMI ! 27 kg/m 2 had signi®cantly higher systolic and diastolic blood pressure, blood glucose and insulin levels following oral glucose tolerance test than those with BMI`27 kg/m 2 . Fasting plasma insulin values were also signi®cantly higher in the BMI ! 27 kg/m 2 subjects (138.5 AE 66.6 vs 111.0 AE 29.9 pmol/l, respectively, P`0.05). Quanti®cation of the area under the curve of the insulin secretion showed hyperinsulinaemia in 64.1% of patients with BMI ! 27 kg/m 2 compared to 28.5% in the group with BMI`27 kg/m 2 (P`0.01). Plasma insulin values were positively related to triglyceridaemia. There were no differences in the plasma lipid values between the two FCH groups. We conclude that fasting and post-glucose stimulated plasma insulin levels are frequent ®ndings in patients with FCH when compared with control subjects of similar age, gender and BMI. Moreover, obesity (BMI ! 27 kg/m 2 ) exacerbates the hyperglycaemia, hyperinsulinaemia and blood pressure values in these FCH subjects. These factors, together with lipid abnormalities, can predispose to the elevated risk of cardiovascular disease observed in FCH subjects.
Introduction
Familial combined hyperlipidaemia (FCH), ®rst described in 1973 as a dyslipidaemic syndrome, 1±5 was identi®ed by the study of families of young myocardial infarction survivors. The principle characteristics are an elevation in the plasma concentration of apolipoprotein B (apo B) and a variable lipoprotein phenotype de®ned by the elevation of low density lipoprotein (LDL; phenotype IIa), of very low density lipoprotein (VLDL; phenotype IV) or of both (phenotype IIb). The disease is transmitted as an autosomal dominant (although a polygenic inheritance cannot be discounted), is rarely present in childhood and is associated with an elevated risk of ischaemic heart disease in the fourth or ®fth decade of life.
6±9
Together with the elevated concentration of VLDL and/or LDL, a qualitative alteration in the composition of the lipoproteins 10±12 and, frequently, a diminution of high density lipoprotein (HDL) co-exist in FCH.
Elevated risk of cardiovascular disease (CVD) is clearly related to lipoprotein abnormalities but other risk factors such as obesity, hypertension, alterations in glucose metabolism, insulin resistance and hyperinsulinaemia are also implicated. 13±21 Hyperinsulinaemia has been considered an independent CVD risk factor in the general population 16±18 but whether this is independent of a frequently-observed associated increase in VLDL has been questioned. 22 Insulin resistance is known to induce hypertension, cellular proliferation in the arterial wall and, among the various abnormalities of lipoprotein distributions, an abnormal low density lipoprotein particle type (smaller and denser; pattern B) which has been considered a marker of insulin resistance. 23, 24 Central trunk (intraabdominal) obesity is related to CVD risk through its frequent association with hypertension, metabolic alterations such as dyslipaemia, abnormal glucose tolerance, insulin resistance with hyperinsulinaemia and the elevation of the concentrations of plasminogen activator-inhibitor;
25±28 obesity exacerbates the pre-existing, often sub-clinical, metabolic abnormalities. In the light of these documented associations, we investigated a group of FCH patients so as to evaluate the effect of attendant obesity.
Methods

Subjects
Patients (n 67; 45 male, 22 female) were selected from among those attending the Lipid Clinic at the Hospital Clõ Ânico Universitario de Valencia. Diagnosis of FCH was based on clinical and biochemical evaluation of the probands and all available ®rst-degree relatives. The criteria were the existence of hyperlipidaemia of variable phenotype (IIa, IIb, or IV) amongst the family members; a family history of premature CVD; elevated plasma concentrations of apo B; absence of hyperlipidaemia in family members of less than 20 y of age; changing lipoprotein phenotype in the same individual over time, and absence of xanthomas in the proband and family members. The probands selected were non-smokers and had plasma concentrations of LDL cholesterol (LDL-C) ! 4.1 mmol/l and/or triglycerides (TG) ! 2.3 mmol/l and baseline glucose`7.8 mmol/l. In 11 males, selected on the basis of FCH, presence of ischaemic heart disease (a previous myocardial infarction) was noted from the clinical history. The group studied was composed of 24 subjects (15 male and 9 female) with phenotype IIa (LDL-C ! 4.1 mmol/l and plasma triglyceride`2.3 mmol/l, 27 (19 male and 8 female) with phenotype IIb (LDL-C ! 4.1 mmol/l and plasma triglyceride ! 2.3 mmol/l and 16 (11 male and 5 female) with phenotype IV (LDL-C`4.1 mmol/l and plasma triglyceride ! 2.3 mmol/l). Exclusion criteria were secondary hyperlipidaemias, hepatic or renal disease or a myocardial infarction having occurred less than three years previously. None of the patients was in receipt of any medication known to affect lipid/carbohydrate metabolism. To evaluate the effect of obesity, the subjects were divided into two groups based on a BMI value of 27 kg/m 2 .
29,30
For comparison, a group of 67 clinically-healthy subjects of similar age, gender and BMI were recruited among those attending our hospital's voluntary blood-donor clinic. None had a personal or family history of cardiovascular or metabolic disease and all were non-smokers. As with the probands, none was in receipt of any medication known to affect lipid/carbohydrate metabolism.
The study was approved by the Ethics Committee of the University Hospital and all participants gave fully-informed, written consent before recruitment into the study.
Laboratory analyses
Blood samples for the determination of baseline lipoproteins, glucose and insulin were obtained after an overnight (12 h) fast. Cholesterol and triglycerides were measured using enzymatic methods (Technicon RA Systems). 31, 32 HDL cholesterol (HDL-C) was measured after the precipitation, from plasma, of the apo B-containing lipoproteins with dextran sulphate/ magnesium 33 and VLDL cholesterol (VLDL-C) after the separation of VLDL (density`1.006 g/ml) by ultracentrifugation (18 h, 105 000 6 g, 15 C) in a Ti 50.3 ®xed-angle rotor in a Beckman L8-80 ultracentrifuge. 34 A value for LDL cholesterol (LDL-C) was obtained by subtraction from the plasma total cholesterol (TC) the values for VLDL-C and HDL-C. Apo B was quanti®ed in plasma by immunonephelometry. 35 Oral glucose tolerance test (GTT) was conducted as recommended by WHO Diabetes Study Group 36 using 75 g glucose. Blood for the determination of glucose 37 and insulin 38 was extracted at 0, 30, 60, 90 and 120 min.
Statistical analyses
Analyses were conducted using the Statgraphics program. 39 Comparison of means between groups was by the unpaired Student t-test and one way analysis of variance (ANOVA). Variables that were not normally distributed were compared using the Kurskall±Wallis non-parametric test. Relationships between parameters were by regression analysis and the comparison of proportions with the w 2 test with the correction factor of the exact test of Fisher. Statistical signi®-cance was set at P`0.05.
Results
All values are expressed as means AE s.d. The general characteristics of the study subjects are presented in Table 1 . Of the FCH group, 11 had ischaemic heart disease as evidenced by a myocardial infarction several years previously. Systolic and diastolic pressure were higher in the FCH group relative to control subjects. The plasma concentrations of lipoproteins in the FCH and control groups are also presented in Table 1 together with the levels of statistical difference.
The GTT demonstrated signi®cantly elevated levels of glycaemia at 30, 60, 90 and 120 min and of insulinaemia at 0, 30, 60, 90 and 120 min in FCH patients relative to control subjects ( Table 2 ). The area under the curve (AUC) for insulin secretion was 91124 AE 47334 and 54237 AE 19679 pmol/l/min in FCH patients and control subjects respectively (P`0.01). If hyperinsulinaemia is de®ned as those values above the 90th percentile of control group values, then the percentage of subjects with FCH having hyperinsulinaemia was 34.3% at baseline and 79.1% at 120 min of the GTT.
Sub-grouped of the basis of gender (Table 3) , signi®cant differences were observed in age, blood pressure and the plasma concentration of HDL-C but not for the parameters of glycaemia and insulinaemia. Hence, for these latter measurements, the data from both genders were combined in the statistical analyses.
Sub-grouped on the basis of BMI, the 39 patients with a BMI ! 27 kg/m 2 had, relative to the sub-group with a BMI`27 kg/m 2 , signi®cantly elevated blood pressure values but not of the lipoprotein variables measured (Table 4) . However, irrespective of the sub- Obesity and familial combined hyperlipidaemia JF Ascaso et al group assignment (BMI`or ! 27 kg/m 2 ) all FCH patients had signi®cantly elevated blood pressure and lipoprotein concentrations (except HDL-C) relative to their corresponding control group of subjects.
The same BMI sub-groups, when analysed with respect to glycaemia and insulinaemia ( Table 5 ), showed that both patient sub-groups, relative to the corresponding control subjects, had elevated glycaemia at 30, 60, 90 and 120 min as well as having elevated AUC. For insulin, these values were elevated at all time points. Comparing the patients above and below the 27 kg/m 2 cut-off, signi®cantly higher values of glycaemia at 90 and 120 min as well as the AUC were observed in the obese group. Similar ®ndings were noted with respect to insulin. The percentage of study subjects with hyperinsulinaemia (based on the AUC of insulin secretion) was 64.1% in the obese patients with FCH and 28.5% in the non-obese patients while the corresponding values were 13.1% and 3.5% in the obese and non-obese control subjects, respectively (Table 6 ).
Higher insulinaemia was encountered in patients with elevated plasma triglyceride concentrations. The hyperinsulinaemia correlated signi®cantly with plasma triglyceride, (r 0.34, P`0.02) and systolic and diastolic blood pressure (r 0.33, P`0.02). In the control group of subjects, the signi®cant correlations were with BMI, apo B and the AUC of the glucose response.
The FCH subjects with BMI ! 27 kg/m 2 had a higher percentage of hypertension (71.7%) and glucose intolerance (41%) than FCH subjects with BMI`27 kg/m 2 (32.1%, and 25%, respectively) ( Table 7) . 75217 AE 30575 102546 AE 53916* 46288 AE 12562*** 59872 AE 21967*** * Signi®cantly different (P`0.01) and ** (P`0.05) with respect to FCH patients with BMI`27 kg/m 2 . *** Signi®cantly different (P`0.001) with respect to FCH patients of the same BMI. AUC area under the curve of glucose or insulin response to the 75 g oral glucose load. . *** Signi®cantly different (P`0.01) with respect to the FCH patients of the same BMI. FCH familial combined hyperlipidaemia; BMI body mass index; BP S systolic blood pressure; BP D diastolic blood pressure; TC total (plasma) cholesterol; TG total (plasma) triglycerides; LDL-C low density lipoprotein cholesterol; VLDL-C very low density lipoprotein cholesterol; HDL-C high density lipoprotein cholesterol; Apo B apolipoprotein B.
Discussion
The interest in the investigation of metabolic alterations in FCH is justi®ed on the grounds of the high incidence of ischaemic heart disease found in these patients. It has been demonstrated, for example, that up to 20% of males below the age of 60 y who had survived a myocardial infarction who had FCH. 36 Of our group of patients, 11 had premature ischaemic heart disease; a ®gure representing 28% of the males in the study.
Together with changes in lipoprotein concentrations (increase in LDL-C, VLDL-C, apo B; decrease in HDL-C) qualitative changes in the lipoproteins (triglyceride and apo B enrichment of VLDL and LDL) increase the atherosclerosis risk. 10, 12, 22 Particle size, as well, can be modi®ed as a consequence of an increased turnover of apo B and VLDL leading to the production of smaller, denser LDL particle (pattern B; Reference 25) which appears to possess a higher atherogenic potential.
Hyperinsulinism, as a compensatory response to a state of insulin resistance, has been described as an independent risk factor for cardiovascular disease in the general population. 40 As reported by other authors, 41 we observed signi®cant correlations between hyperinsulinaemia and plasma triglycerides, VLDL-C as well as blood pressure. Hyperinsulinaemia in the basal state has been described as being moderately correlated with concentrations of plasma of apo B and triglycerides. 42, 43 Data regarding insulin resistance are, to-date, limited possibly because of the relationship with abdominal obesity which, per se, produces a certain degree of insulin resistance 44 that would modulate the basal state measurements.
In this present study we encountered baseline hyperinsulinaemia in 38.8% of the patients with FCH. This ®gure increased to 77.6% when assessed by the GTT. The values are signi®cantly higher than those observed in the controls. The data on hyperinsulinaemia when subjects were subdivided by BMI (Table 6) show that FCH signi®cantly associates with hyperinsulinaemia even in the absence of obesity. In the BMI`27 kg/m 2 sub-group, 25% of FCH had basal hyperinsulinaemia compared to 0% in controls; 67.8% had hyperinsulinaemia at 2 h compared to 3.5% in controls; and 28.5% had elevated AUC compared to 3.5% in controls. The observation that hyperinsulinaemia can be present in non obese FCH was also reported by Castro-Cabezas et al. 41 On the other hand, obesity aggravates the condition and causes an increase not only of the hyperinsulinaemia but also of blood pressure and glucose intolerance; all of them being acknowledged risk-factors for CVD.
Conclusions
Having been detected in more than two thirds of the patients investigated, insulin resistance with hyperinsulinaemia must, now, be considered a frequent alteration in FCH. Our results con®rm that, in FCH, a state of insulin resistance with hyperinsulinaemia exists and which is not necessarily related to obesity. However, the presence of obesity aggravates the hyperinsulinaemia and is associated with a signi®cant increase in blood pressure, triglyceridaemia and the LDL-C/HDL-C index. Since these are well-recognised risk factors predisposing to an increased risk of cardiovascular disease, therapeutic regimens should address all these factors in FCH rather than the lipoprotein abnormalities alone.
